Moderna moves closer to personalized cancer therapy

Moderna is developing vaccines and medications based on messenger RNA. This provides body cells with a blueprint for proteins, enabling the immune system to recognize pathogens or tumor cells. The US biotech company gained fame through its COVID-19 vaccine. It primarily generates revenue from vaccine sales, along with income from collaborations and the provision of production capacities. In addition to COVID-19, the current portfolio includes vaccines against the respiratory virus RSV and influenza. Long-term, personalized cancer treatments are...